Active Pharmaceutical Substance Production Technology using Lactobacillus fermentum and Lactobacillus cellobiosus for the treatment of Intestinal Infections

One of the main problems in the production of probiotic preparations is biomass production preserving the initial properties of the selected strain or strain association. The study aimed to develop a production technology for an active pharmaceutical substance (APS) to produce a medicinal probiotic preparation to treat acute intestinal infections. A study conducted in 2023 in the laboratory of Industrial Microbiology LLP used Lactobacillus fermentum 30 and Lactobacillus cellobiosus 36 strains cultivated in a liquid medium at 37°C to produce APS, evaluating their antagonistic activity and the absence of bacteriophages. Quality control included pH measurement, sequencing of microorganisms, determination of the number of viable cells, and testing of antagonistic activity by diffusion in agar. The APS included an association of probiotic lactic acid bacteria L. fermentum 30 and L. cellobiosus 36, which has high antagonistic activity against pathogens of human intestinal infections. The production technology for APS based on the co-cultivation of L. fermentum 30 and L. cellobiosus 36 strains by periodic fermentation can be used to produce probiotic medicinal preparations based on the association of lactic acid bacteria.